Last reviewed · How we verify
Secondary malignant neoplasm of female breast
Approved treatments
- OGIVRI · MYLAN GMBH
- Cytadren · Novartis
- Herceptin · Roche
Trastuzumab inhibits proliferation of HER2-overexpressing tumor cells and mediates antibody-dependent cellular cytotoxicity. - Herceptin · Roche
HER2-targeted antibody-drug conjugate delivering microtubule inhibitor DM1 to HER2-overexpressing cells. - Herceptin · National Cancer Institute (NCI)
- Trastuzumab (Herceptin) · Pfizer Inc.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Secondary malignant neoplasm of female breast patent landscape — cliff calendar, originator estates, attackable patents
- Secondary malignant neoplasm of female breast treatment landscape brief
- Secondary malignant neoplasm of female breast treatment updates RSS
Frequently asked questions about Secondary malignant neoplasm of female breast
What drugs treat Secondary malignant neoplasm of female breast?
Tracked treatments include OGIVRI, Cytadren, Herceptin, Trastuzumab (Herceptin).
What is the treatment for Secondary malignant neoplasm of female breast?
Standard treatment for Secondary malignant neoplasm of female breast includes OGIVRI, Cytadren, Herceptin, Trastuzumab (Herceptin). See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Secondary malignant neoplasm of female breast patent cliff · Secondary malignant neoplasm of female breast CI report
- Treatment: OGIVRI · MYLAN GMBH
- Treatment: Cytadren · Novartis
- Treatment: Herceptin · Roche
- Treatment: Herceptin · Roche
- Treatment: Herceptin · National Cancer Institute (NCI)
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing